# OnCo record veritac-2 (trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/trials/veritac-2/>
  a schema:MedicalTrial ;
  onco:kind "trial" ;
  schema:identifier "veritac-2", "NCT05654623" ;
  schema:name "VERITAC-2"@en ;
  schema:description "The trial that got the first PROTAC approved, with benefit only in tumours with ESR1 mutations."@en ;
  schema:url <https://onco.cc/trials/veritac-2/> ;
  schema:dateModified "2026-09-04"^^xsd:date ;
  schema:citation <https://clinicaltrials.gov/study/NCT05654623> ;
  onco:status "mixed" ;
  onco:phase "3" ;
  schema:startDate "2023-03-03" ;
  onco:cancers <https://onco.cc/cancers/breast-hr-positive/> ;
  onco:technologies <https://onco.cc/technologies/endocrine-therapy/>, <https://onco.cc/technologies/protac-degrader/> ;
  onco:targets <https://onco.cc/targets/estrogen-receptor/> ;
  onco:drugs <https://onco.cc/drugs/vepdegestrant/> ;
  onco:companies <https://onco.cc/companies/arvinas/> ;
  onco:keyPapers <https://onco.cc/key-papers/paper-protac-concept-sakamoto-pnas-2001/> .